within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BX10_Concizumab;

model Concizumab
  extends Pharmacolibrary.Drugs.ATC.B.B02BX10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B02BX10</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Concizumab is a humanized monoclonal antibody that inhibits tissue factor pathway inhibitor (TFPI) and is developed for the treatment of hemophilia A and B with or without inhibitors. It is under clinical investigation and not yet widely approved or marketed.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were assessed in healthy subjects, adolescents, and patients with hemophilia A and B. Key phase 1/2/3 studies indicate subcutaneous administration with dose proportional increases in exposure.</p><h4>References</h4><ol><li><p>Shapiro, AD, et al., &amp; Oldenburg, J (2019). Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. <i>Blood</i> 134(22) 1973–1982. DOI:<a href=\"https://doi.org/10.1182/blood.2019001542\">10.1182/blood.2019001542</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31444162/\">https://pubmed.ncbi.nlm.nih.gov/31444162</a></p></li><li><p>Matsushita, T, et al., &amp; Jiménez-Yuste, V (2023). Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. <i>The New England journal of medicine</i> 389(9) 783–794. DOI:<a href=\"https://doi.org/10.1056/NEJMoa2216455\">10.1056/NEJMoa2216455</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37646676/\">https://pubmed.ncbi.nlm.nih.gov/37646676</a></p></li><li><p>Eichler, H, et al., &amp; Chowdary, P (2018). A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. <i>Journal of thrombosis and haemostasis : JTH</i> 16(11) 2184–2195. DOI:<a href=\"https://doi.org/10.1111/jth.14272\">10.1111/jth.14272</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30137664/\">https://pubmed.ncbi.nlm.nih.gov/30137664</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Concizumab;
